Enlivex Therapeutics (ENLV)
(Delayed Data from NSDQ)
$1.51 USD
+0.01 (0.67%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $1.45 -0.06 (-3.97%) 7:58 PM ET
2-Buy of 5 2
F Value B Growth A Momentum B VGM
Price, Consensus and EPS Surprise
ENLV 1.51 +0.01(0.67%)
Will ENLV be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ENLV based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ENLV
All You Need to Know About Enlivex Therapeutics (ENLV) Rating Upgrade to Buy
Enlivex (ENLV) Stock Plummets 51% in a Week: Here's Why
ENLV: What are Zacks experts saying now?
Zacks Private Portfolio Services
New Strong Buy Stocks for November 3rd
New Strong Buy Stocks for October 27th
New Strong Buy Stocks for October 19th
Other News for ENLV
Enlivex Therapeutics initiated with bullish view at EF Hutton, here's why
Enlivex Receives Regulatory Authorization For The Initiation Of A Phase I Clinical Trial To Evaluate Allocetra In Patients With Psoriatic Arthritis
Enlivex Advances Psoriatic Arthritis Treatment with Allocetra™
Enlivex receives regulatory authorization for Phase I trial of Allocetra
Enlivex Therapeutics and Biotricity Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV